Abstract 197TiP
Background
Gastric cancer (GC) is the fourth leading cause of cancer death worldwide, with disproportionate incidence and mortality rates reported for people from Eastern Asia. Capecitabine + oxaliplatin (CAPOX) is a standard first-line treatment for advanced GC. Recently, Claudin (CLDN)18.2 has emerged as a promising targetable biomarker. In healthy tissue, CLDN18.2 is confined to gastric mucosa tight junctions. Upon malignant transformation, cell polarity perturbations lead to exposure of CLDN18.2 on the cell surface. Zolbetuximab is a chimeric IgG1 monoclonal antibody that specifically binds to CLDN18.2 and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. In a randomized phase 2 study (NCT01630083), patients with CLDN18.2+ advanced GC/GEJ treated with zolbetuximab + epirubicin, oxaliplatin, and capecitabine (EOX) showed prolonged survival compared with EOX alone.
Trial design
This phase 3, double-blind, placebo-controlled study (NCT03653507) will enroll ∼500 adult patients from global sites, including sites in China, Japan, Republic of Korea, and Thailand. Patients with CLDN18.2+/HER2– locally advanced unresectable or metastatic GC or GEJ not previously treated with chemotherapy will be eligible. Patients will be randomized 1:1 to receive zolbetuximab + CAPOX or placebo + CAPOX. Zolbetuximab will be administered as an 800-mg/m2 IV loading dose followed by 600 mg/m2 Q3W in combination with CAPOX. Central testing of tumor tissue will determine CLDN18.2 and HER2 status (if unknown); patients will be considered CLDN18.2+if ≥ 75% of tumor cells demonstrate moderate-to-strong membranous IHC staining. The primary objective is to compare progression-free survival of zolbetuximab + CAPOX vs placebo + CAPOX. The key secondary efficacy endpoint is overall survival. Objective response rate, duration of response, the safety/tolerability profile, PK profile, and immunogenicity of zolbetuximab are other secondary endpoints.
Clinical trial identification
NCT03653507.
Legal entity responsible for the study
Astellas Pharma US, Inc.
Funding
Astellas Pharma US, Inc.
Disclosure
J. Ajani: Advisory / Consultancy, Research grant / Funding (institution): Astellas. S-E. Al-Batran: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: SERVIER; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Celgene; Speaker Bureau / Expert testimony: Nordic Bioscience ; Research grant / Funding (institution): Hospira; Research grant / Funding (institution): Medac; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Roche Pharma AG; Research grant / Funding (institution): Vifor Pharma. Y-J. Bang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Genetech/Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck Serano; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy: Taiho; Advisory / Consultancy, Research grant / Funding (institution): Daiich-Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): BeiGene; Advisory / Consultancy, Research grant / Funding (institution): GreenCross; Advisory / Consultancy: Samyang Biopharm; Advisory / Consultancy: Hanmi; Advisory / Consultancy, Research grant / Funding (institution): Genexine; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Boston Biomedical. D. Catenacci: Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Gritstone; Honoraria (self), Advisory / Consultancy: Taiho; Honoraria (self), Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy: Daichii Sankyo. P. Enzinger: Advisory / Consultancy: Merck; Advisory / Consultancy: Astellas; Advisory / Consultancy: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: Loxo; Advisory / Consultancy: Taiho. D. Ilson: Honoraria (self): Astellas. S. Kim: Advisory / Consultancy: Astellas. F. Lordick: Advisory / Consultancy: Astellas; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: AstraZeneca. K. Shitara: Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Takeda; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self): Novartis; Honoraria (self): AbbVie; Honoraria (self): Yakult; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Chugai Pharma; Advisory / Consultancy, Research grant / Funding (institution): MSD; Research grant / Funding (institution): Medi Science. E. Van Cutsem: Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy: Incyte; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Servier; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Ipsen. A. Arozullah: Full / Part-time employment: Astellas. J. Wook Park: Full / Part-time employment: Astellas Pharma Global Development Inc. All other authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract